Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New heart stent under observation in 1,100 patients

NCT ID NCT06841510

Disease control Sponsor: Genoss Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study is tracking over 1,100 people with coronary artery disease who received the GENOSS SES stent, a device that props open blocked heart arteries. Researchers are monitoring heart-related deaths, heart attacks, and the need for repeat procedures over time. The goal is to see how well the stent works in real-world use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GENOSS SES (a drug-eluting stent)
What this could lead to
If successful, this could confirm that the GENOSS SES stent is a safe and effective option for treating blocked heart arteries.
What could go wrong
This is an observational study, not a randomized trial, so results may be less definitive. Stents carry risks like blood clots or re-narrowing of the artery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,118 people

The number who actually took part.

Started

Apr 2018

Expected to finish

Nov 2025

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with coronary artery disease treated with GENOSS SES

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients of 19 and over 2. Patients with coronary artery disease treated with GENOSS SES 3. Participants who voluntarily decide to participate in this clinical trial, agree to the study protocol and clinical follow-up plan, and provide written informed consent as study participants Exclusion Criteria: 1. Patients who are contraindicated in the use of heparin, aspirin, clopidogrel, sirolimus, cobalt chromium and contrast agents 2. Patients who are pregnant or planning to become pregnant 3. Patients with a planned surgery to discontinue antiplatelet agents within 12 months 4. Patients with a life expectancy of less than 1 year 5. Patient with cardiogenic shock at the time of hospitalization and had a low chance of survival based on medical judgment. 6. Patients who have already received treatment with another DES (Drug Eluting Stent) or BMS (Bare Metal Stent) at the time of registration 7. Patients participating in randomized controlled trials using other medical devices

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary arterial disease (CAD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary arterial disease (CAD)

Contacts and locations

Locations

  • Seoul National University Bundang Hospital

    Seongnam, 13620, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.